APG Asset Management N.V. Raises Stock Position in Moderna, Inc. (NASDAQ:MRNA)

APG Asset Management N.V. lifted its stake in Moderna, Inc. (NASDAQ:MRNA) by 848.2% in the 4th quarter, HoldingsChannel reports. The firm owned 227,819 shares of the company’s stock after buying an additional 203,792 shares during the quarter. APG Asset Management N.V.’s holdings in Moderna were worth $9,148,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Advisory Services Network LLC boosted its position in Moderna by 543.1% during the 4th quarter. Advisory Services Network LLC now owns 19,603 shares of the company’s stock valued at $815,000 after acquiring an additional 16,555 shares in the last quarter. Capula Management Ltd purchased a new position in shares of Moderna in the 4th quarter valued at approximately $246,000. Renaissance Technologies LLC boosted its position in shares of Moderna by 225.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company’s stock valued at $42,027,000 after purchasing an additional 700,458 shares in the last quarter. Invesco Ltd. grew its stake in Moderna by 24.3% in the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company’s stock worth $208,169,000 after purchasing an additional 979,858 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in Moderna in the fourth quarter worth $374,000. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 8.1 %

Shares of MRNA stock opened at $24.50 on Friday. The stock has a market capitalization of $9.47 billion, a P/E ratio of -2.64 and a beta of 2.23. The firm’s 50 day moving average is $31.72 and its 200 day moving average is $41.27. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $170.47.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of research reports. Berenberg Bank boosted their target price on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Leerink Partners dropped their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and decreased their target price for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Morgan Stanley dropped their price target on Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Finally, UBS Group reduced their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.